Skip to content

Christina Luddy

4 papers in the library · 213 citations · publishing 2018-2022

Papers

Sort Most recent Most cited

Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial

Headache: The Journal of Head and Face Pain November 1, 2022 Christina Luddy, Yutong Zhu, Hayley Lindsey et al. 75 citations

Abstract Objective Using a patient‐informed regimen, we conducted an exploratory randomized, double‐blind, placebo‐controlled study to systematically investigate the effects of psilocybin in cluster headache. Background Sustained reductions in cluster headache burden after limited quantities of psilocybin‐containing mushrooms are anecdotally reported, although to date there are no controlled...

DOI: 10.1111/head.14420 (opens in new tab) Psilocybin Cluster headache Randomized controlled trial Anesthesia +4

Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).

Psychopharmacology May 2022 Anahita Bassir Nia, Maria J Orejarena, Leigh Flynn et al.

Cannabis is the most common illicit drug used in the USA and its use has been rising over the past decade, while the historical gap in rates of use between men and women has been decreasing. Sex differences in the effects of cannabinoids have been reported in animal models, but human studies are sparse and inconsistent. We investigated the sex differences in the acute subjective,...

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.

Neurotherapeutics 2021 Emmanuelle A. D. Schindler, R Andrew Sewell, Christopher Gottschalk et al. 138 citations

While anecdotal evidence suggests that select 5-hydroxytryptamine 2A (5-HT2A) receptor ligands, including psilocybin, may have long-lasting therapeutic effects after limited dosing in headache disorders, controlled investigations are lacking. In an exploratory double-blind, placebo-controlled, cross-over study, adults with migraine received oral placebo and psilocybin (0.143 mg/kg) in 2 test...

DOI: 10.1007/s13311-020-00962-y (opens in new tab) Full text (opens in new tab) Psilocybin Single dose Migraine headache Lasting therapeutic effects +8

The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans.

Journal of Psychopharmacology December 2018 Douglas L Boggs, Jose A Cortes-Briones, Toral Surti et al.

Binding studies have demonstrated that levels of the cannabinoid receptor type-1 are highest in the basal ganglia and cerebellum, two areas critical for motor control. However, no studies have systematically examined the dose-related effects of intravenous delta-9-tetrahydrocannabinol, the primary cannabinoid receptor type-1 partial agonist in cannabis, on broad domains of psychomotor function...